Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Korro Bio (KRRO) Research & Development (2019 - 2025)

Korro Bio (KRRO) has disclosed Research & Development for 6 consecutive years, with $13.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 13.43% year-over-year to $13.8 million, compared with a TTM value of $71.6 million through Sep 2025, up 874.16%, and an annual FY2024 reading of $63.6 million, up 2445.44% over the prior year.
  • Research & Development was $13.8 million for Q3 2025 at Korro Bio, down from $21.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $21.0 million in Q2 2025 and bottomed at -$39.3 million in Q4 2023.
  • Average Research & Development over 5 years is $11.8 million, with a median of $14.0 million recorded in 2023.
  • The sharpest move saw Research & Development crashed 1245.95% in 2023, then surged 143.13% in 2024.
  • Year by year, Research & Development stood at $12.8 million in 2021, then plummeted by 73.09% to $3.4 million in 2022, then plummeted by 1245.95% to -$39.3 million in 2023, then skyrocketed by 143.13% to $17.0 million in 2024, then fell by 18.52% to $13.8 million in 2025.
  • Business Quant data shows Research & Development for KRRO at $13.8 million in Q3 2025, $21.0 million in Q2 2025, and $19.7 million in Q1 2025.